A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Jonker, D J Rosen, L S Sawyer, M B de Braud, F Wilding, G Sweeney, C J Jayson, Gordon C McArthur, G A Rustin, G Goss, G
Jonker, D J
Rosen, L S
Sawyer, M B
de Braud, F
Wilding, G
Sweeney, C J
Jayson, Gordon C
McArthur, G A
Rustin, G
Goss, G
Citations
Altmetric:
Abstract
This study was designed to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of brivanib in patients with advanced/metastatic solid tumors.
Description
Date
2011-06
Publisher
Collections
Keywords
Type
Article
Citation
A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. 2011, 22 (6):1413-9 Ann Oncol